STOCK TITAN
  1. Home
  2. News
  3. RPRX

Royalty Pharma plc - RPRX STOCK NEWS

Welcome to our dedicated news page for Royalty Pharma plc (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Royalty Pharma plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Royalty Pharma plc's position in the market.

News
Royalty Pharma Reports Third Quarter 2023 Results
Rhea-AI Summary
Royalty Pharma plc (Nasdaq: RPRX) reported net cash provided by operating activities (GAAP) of $574 million and Adjusted Cash Receipts of $637 million for the third quarter of 2023, raising the 2023 guidance to $2,950 to $3,000 million. The company has announced transactions of up to $3.8 billion year-to-date, including $2.1 billion in upfront payments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
earnings
-
News
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
Rhea-AI Summary
Royalty Pharma acquires additional royalties on Roche's Evrysdi for $1.0 billion upfront
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
none
-
News
Royalty Pharma Declares Fourth Quarter 2023 Dividend
Rhea-AI Summary
Royalty Pharma plc Approves Dividend Payment for Q4 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags
dividends earnings
News
Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
Rhea-AI Summary
Royalty Pharma to report Q3 2023 financial results on November 8
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
earnings
-
News
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
Rhea-AI Summary
Royalty Pharma appoints Eric Schneider as Senior VP and CTO, emphasizing technology innovation and data capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
management
-
News
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
Rhea-AI Summary
Royalty Pharma and Ascendis Pharma enter into a $150 million synthetic royalty funding agreement for Skytrofa
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
none
News
Royalty Pharma to Present at Upcoming Investor Conferences
Rhea-AI Summary
Royalty Pharma to participate in investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
conferences
-
News
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
Rhea-AI Summary
Royalty Pharma acquires synthetic royalty on Ferring's Adstiladrin gene therapy for up to $500 million. Ferring receives $300 million upfront and potential $200 million milestone payment. Royalty Pharma to acquire 5.1% royalty on US net sales, increasing to 8.0% upon milestone payment. Positive investment demonstrating confidence in Adstiladrin's potential. Adstiladrin aims to become new standard of care for high-risk bladder cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
none
-
News
Royalty Pharma Reports Second Quarter 2023 Results
Rhea-AI Summary
Royalty Pharma plc (Nasdaq: RPRX) reported strong financial results for Q2 2023, with net cash provided by operating activities of $608 million and Adjusted Cash Receipts of $545 million. They raised their 2023 guidance for Adjusted Cash Receipts to $2,900 to $2,975 million, reflecting a 6% to 10% underlying growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
earnings
News
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
Rhea-AI Summary
Royalty Pharma plc (Nasdaq: RPRX) to report Q2 2023 financial results on August 8, 2023. Conference call and webcast at 8:00 a.m. ET. Visit company website for details and replay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
earnings
Stock RPRX logo
Royalty Pharma plc

Nasdaq:RPRX

RPRX Rankings

#689 Ranked by Market Cap
#4238 Ranked by Stock Gains
#1131 Ranked by Dividends

RPRX Stock Data

16.86B
383.82M
3.83%
72.1%
2.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About RPRX

royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma’s strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott’s humira®, j&j/merck’s remi